Drug intelligence / Profile preview

Algavak M

Development stage: Unknown
Lead developer: Vector-BiAlgam
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Algavak M is an inactivated whole-virus vaccine developed by the Russian company Vector-BiAlgam for the prevention of hepatitis A. It contains 50 ELISA units of inactivated hepatitis A virus (HAV) antigen per dose, adsorbed onto aluminum hydroxide (0.5 mg) which serves as an adjuvant. The vaccine is produced in accordance with international GMP standards and is formulated without antibiotics or preservatives. Administered via intramuscular injection, a full course of vaccination induces long-term specific immunity in 90-95% of recipients. It was officially registered in the Russian State Register of Medicinal Products in 2011 and is utilized in Russia and several CIS countries.

Brand names: Algavak M
Other names: Hepatitis A virus vaccine (inactivated)Algavac M

Beyond the preview

Go deeper on Algavak M.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algavak M.

Explore the full profile